The European Union's drugs regulator on Thursday recommended approval of Eisai and Biogen's Leqembi for some patients with ...

Europe's medicines watchdog on Thursday partially approved a marketing request for a long-awaited new treatment for Alzheimer ...

The AD risk factors/hits include high exposure to traffic-related air pollution (TRAP) and infections, as well as factors ...

Reversing an earlier decision, European regulators recommended that an Alzheimer’s therapy from Eisai and Biogen should be ...

The EMA’s Committee for Medicinal Products for Human Use has issued a positive recommendation for Eisai and Biogen’s Leqembi ...

Biogen’s stock rose 1% Thursday, after Europe’s pharmaceutical regulator issued a positive opinion on the Alzheimer’s disease ...

University of Washington-led research, published in 2023, discovered microglia in the brains of people with Alzheimer's ...

A warning has been issued over drinking habits that could actually accelerate Alzheimer’s disease. New research published in ...

As we count down toward the December readout of Cassava Sciences’ simufilam Phase 3 clinical trial in Alzheimer’s disease, it ...

Upon reexamination, the European Medicines Agency has made a U-turn on Eisai and Biogen’s Alzheimer’s disease drug Leqembi. | ...

Researchers discovered that the enzyme TYK2 alters the tau protein, promoting its accumulation in the brain, a process linked ...

November is Alzheimer's Awareness Month and 7 News met Grand Island couple Tom and Michele Drabik, who shared their experience with the disease.